Specified Drug Use-results Survey of Betanis Tablets

Astellas Pharma Inc300 enrolled

Overview

To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Overactive Bladder

Interventions

mirabegronDRUG

oral

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosed as OAB and treated with mirabegron * diagnosed as glaucoma (including normal tension glaucoma) * having intraocular pressure measurement conducted more than twice within six months before the start of the mirabegron treatment

Locations (7)

Unnamed facility

Chugoku, Japan

Unnamed facility

Chūbu, Japan

Unnamed facility

Kansai, Japan

Unnamed facility

Kanto, Japan

Unnamed facility

Kyushu, Japan

Outcomes

Primary Outcomes

The occurrence of ocular adverse events such as increased intraocular pressure and worsening of glaucoma

Time frame: 12 weeks

Secondary Outcomes

Changes in OABSS (Over Active Bladder Symptoms Score)

OABSS is judged by investigator

Time frame: Baseline and 12 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.